Don’t waste your time – keep track of how NFP affects the US dollar!

Data collection notice

FBS maintains a record of your data to run this website. By pressing the “Accept” button, you agree to our Privacy policy.

Join the Facebook community of FBS!

Beginner Forex book

Beginner Forex book will guide you through the world of trading.

Email tooltip

Thank you!

We've emailed a special link to your e-mail.
Click the link to confirm your address and get Beginner Forex book for free.

FBS Mobile Personal Area

FREE

View
Novavax is Under Attack

Novavax is Under Attack

Information is not investment advice

Novavax is Under Attack

Novavax tried to fulfill more than 2 billion doses of vaccine, but the campaign is now delaying too much due to production lags. Is that a sell sign for investors?

The plans were too big

Novavax (NVAX), the world’s vaccine distributor has been counting on U.S. companies to provide more than 2 billion doses to lower and middle-income countries by the end of 2022. In case of success, the company would have a crucial role in the fight with Covid-19.

But the campaign has already been delayed significantly because of production lags and is now likely to fall short by more than 1 billion doses as a key supplier faces significant hurdles in proving it can manufacture a shot that meets regulators’ quality standards.

The U.S. government invested $1.6 billion in Novavax in 2020 — the most it devoted to any vaccine maker at the time — in hopes that it would offer the world another option for a safe and effective vaccine to help protect against Covid-19. But the company has consistently run into production problems. The methods it used to test the purity of the vaccine have fallen short of regulators’ standards and the company has not been able to prove that it can produce high-quality vaccine shots.

Another big problem is that purity levels that have been set by FDA are not met by Novavax. The company only has around 70% purity in every batch of the vaccines, with requirements are at 90%.

What about the stock?

Falling by more than 50% since September 24, the price chart of the NVAX is still looking bearish. Considering given problems with vaccines production and distribution, we suppose the company to plunge even more. This means the support levels now are not the pivotal points: the price can react to them but will probably continue its downtrend. Don’t forget to take your profit on these levels.  

Novavax daily chart

Support: 120.0; 103.0; 78.0

Resistance: 160.0; 190.0; 260.0

 NVAXDaily.png

Similar

A New Meta

What will change for investors and traders as Facebook completes the transformation?

Euro May Start a Rally

On October 28 European Central Bank held a press conference. Inflation has hit Europe and now the time has come for more profound steps in the fight with the post-pandemic economy. What should we know to trade these events?

Popular

Turkish Lira Is at Record Lows

USD/TRY belongs to the exotic group of Forex currency pairs, that’s why traders don’t trade it regularly. However, these days this pair is in the focus of all the trading community!

Choose your payment system

Be on top of your game

Callback

Please fill in the form below so we can contact you

Select the best time for us to call you. We give calls from Monday to Friday in suggested intervals. In case we couldn't get through, we will try again at the same time the next day. For getting real-time assistance, use FBS chat.

We provide only English-speaking callbacks. If you prefer any other languages, contact the support team.

We will call you at the time interval that you chose

Change number

Your request is accepted.

We will call you at the time interval that you chose

Next callback request for this phone number will be available in 00:30:00

If you have an urgent issue please contact us via
Live chat

Internal error. Please try again later